ShangPharma to Report Second Quarter 2012 Financial Results on August 20, 2012

SHANGHAI, Aug. 6, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) (“ShangPharma” or the “Company”), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2012 on August 20, 2012. Management will host a conference call to discuss the results at 8:00AM U.S. Eastern Time on August 20, 2012 (8:00PM Beijing Time on August 20, 2012).

Conference Call

Mr. Michael Xin Hui, founder and Chief Executive Officer, and Mr. William Dai, Chief Financial Officer, will discuss the results and take questions following the prepared remarks.

Dial-in details for the live conference call are as follows:

International: +1-718-354-1231
United States: +1-866-519-4004
United Kingdom: 080-8234-6646
Hong Kong: +852-2475-0994

Passcode: SHP

A live webcast of the conference call will be available on the investor relations section of the Company’s website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from August 20, 2012, 11:00AM U.S. Eastern Time, to August 27, 2012, 11:59PM U.S. Eastern Time. The dial-in details for the replay are as follows:

International: +61-2-8235-5000
Passcode: 17558472

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma’s services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, please contact:

ShangPharma
William Dai
Chief Financial Officer
Email: ir@shangpharma.com

Brunswick Group
Josh Gartner
Email: shangpharma@brunswickgroup.com
Phone: 86-10-5960-8600

SOURCE ShangPharma Corporation

MORE ON THIS TOPIC